It is a product of URIT. On the basis of the original urine routine analysis workflow, US-3000 series has added urine-specific protein module and urine biochemistry detection module to realize one-stop detection of urine physics, dry chemistry, formed element, specific protein, and biochemical quantification. On the basis of all-in-one machine, US-1680 series adds online functions to meet the needs of different markets.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Roche said Tuesday that it secured US Food and Drug Administration 510(k) clearances for a pair of assays to aid diagnosis of Alzheimer's disease measuring levels of beta-amyloid and tau proteins.

POCT industry started late in China, the overall market size is still small currently, and the penetration rate in hospitals and other terminal sites is low, so there is a huge potential development space. Qianzhan Institute predicts that from 2022-2027, the Chinese POCT market will rise by about 9% CAGR to about 18 billion yuan in 2027.

Prenetics Global Limited, a leading genomics-driven health sciences company, and Prof. Dennis Lo today announce they have entered into an agreement to establish a joint venture named Insighta. The board of directors of Prenetics Global Limited has unanimously approved the transaction.

Oxford Nanopore Technologies (Oxford Nanopore) and leading China-based diagnostic companies, Zheijiang Digena Diagnostic Technology Co. Ltd (Digena) and Wuhan Dgensee Clinical Laboratory Co., Ltd (Dgensee), today announced a series of strategic collaborations that aim to bring nanopore sequencing technology and instruments to the clinical market in China.

As the world's most active emerging market, the influence of China's market on the entire global scientific instrument market is rising year by year, and revenue in China has become the most important part of the global performance of many multinational companies.

Rice University bioengineers said this week that they have demonstrated a low-cost, point-of-care DNA test for HPV infections that could make cervical cancer screening more accessible in low- and middle-income countries where the disease kills more than 300,000 women each year.

Quest Diagnostics said it completed its previously announced acquisition of Haystack Oncology.

Recently, the Chinese Center for Disease Control and Prevention (CDC) issued a Notice on the public consultation of 2 standards.

Paige is enhancing its suite of AI-enabled solutions designed to support pathologists in the diagnosis of breast cancer while decreasing subjectivity and the tedium of manual analysis.

The US Food and Drug Administration announced on Tuesday that it has launched a voluntary pilot program intended to reduce the risks of laboratory-developed tests used to select patients for oncology therapies.